Our results taken in the context of increasing focus on GLP-1 analogues and other gut hormones in pharmacological obesity treatment [16, 17], adds further value towards understanding the complexities of appetite regulation in this population. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.